GILD
Gilead Sciences Inc
150.10$
-0.5%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +31.1% | -6.9% | -14.1% | -15.2% | +1.5% | +10.0% | +10.6% | -0.1% | -0.6% | +6.0% | +2.4% | |
| – | +5.8% | +6.4% | +2.6% | +11.0% | -3.7% | -2.2% | +44.4% | -14.3% | +2.6% | +7.7% | -0.3% | |
| – | +35.7% | -8.7% | -16.8% | -20.5% | +2.9% | +13.2% | +2.9% | +4.4% | +25.4% | -17.0% | +3.1% | |
| – | +5.6% | +69.1% | -26.8% | +5.0% | +3.4% | +24.3% | -8.7% | +8.2% | +14.9% | +3.3% | -1.8% | |
| – | +14.9% | -0.8% | +14.1% | +4.6% | -11.3% | +20.0% | +4.5% | +8.5% | +32.8% | -59.4% | -17.1% | |
| – | +10.3% | +31.9% | -10.4% | +4.8% | +5.8% | +90.2% | -32.8% | +32.5% | -17.4% | +76.5% | -44.8% | |
| – | +45.4% | -20.5% | -19.9% | -41.9% | -47.7% | -5.0% | +143.6% | -26.1% | +3.8% | -78.1% | +604.0% | |
| – | +67.0% | +40.1% | +16.0% | -3.7% | -7.6% | -1.1% | +1.7% | -6.6% | +1.0% | +3.5% | +4.8% | |
| – | +45.8% | -21.1% | -20.9% | -42.4% | -33.8% | -67.7% | +396.0% | -29.8% | +18.0% | -89.9% | +1,319.7% | |
| – | +27.0% | +1.6% | +146.2% | -73.7% | -108.7% | – | +31.5% | -39.9% | -199.9% | – | +509.5% | |
| – | +49.6% | -25.4% | -65.7% | +17.9% | -1.3% | -97.7% | +4,961.0% | -26.2% | +23.4% | -91.5% | +1,672.9% | |
| – | +43.7% | -18.0% | -17.1% | -35.3% | -26.6% | -45.3% | +174.1% | -21.9% | -14.1% | -41.7% | +206.3% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.